Cyclophosphamide Plus Transplantation of Partially HLA-mismatched, CD8+ T Cell-depleted Peripheral Blood Cells for Patients With Myelodysplastic Syndrome , Refractory Acute Myeloid Leukemia, Refractory Lymphoma or Myeloproliferative Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00356928
Recruitment Status : Active, not recruiting
First Posted : July 27, 2006
Last Update Posted : July 13, 2017
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : May 2020
  Estimated Study Completion Date : December 2020